Key Highlights

  • Prelude Therapeutics (NASDAQ:PRLD) rose 6.15% pre-market on a Partnership tag, with a Market Value of USD 298 million and an RSI of 33.9, on 24,721 shares, on 24,721 shares, on 24,721 shares, on 24,721 shares.
  • Savara (NASDAQ:SVRA) rose 5.37% pre-market ahead of a November 22 FDA decision, with a market value of USD 994 million and an RSI of 41.2, on 1,147 shares, on 1,147 shares, on 1,147 shares.
  • Obsidian Therapeutics (NASDAQ:OBX) rose 5.16% pre-market after a 67% melanoma response rate, with a market value of USD 790 million and an RSI of 33.8, on 100 shares, on 100 shares, on 100 shares.
  • Olema Pharmaceuticals (NASDAQ:OLMA) rose 4.76% pre-market after a Phase 3 delay, with a market value of USD 644 million and an RSI of 20.7, on 182 shares, on 182 shares, on 182 shares, on 182 shares.

Prelude Therapeutics (NASDAQ:PRLD): Below Its April Offering Price

Prelude Therapeutics (NASDAQ:PRLD) rose 6.15% pre-market to a listed USD 3.74 on 24,721 shares, with a market Capitalization of USD 298 million and an RSI of 33.9 labeled Down. The screener tags a product or partnership item for Prelude, but the specific October 13 announcement was not located in company filings or wire releases reviewed. Prelude's most recent update, on August 11, showed R&D expense falling to USD 16.1 million from USD 25.8 million and net loss narrowing to USD 13.9 million from USD 31.2 million. In April 2026 the company raised USD 90.0 million at USD 4.44 a share in an offering led by RA Capital Management, and the USD 3.74 listed price is about 16% below that offer price, simple arithmetic. Cash, cash equivalents, restricted cash and marketable securities were USD 155.2 million at June 30, or about half of the USD 298 million market value. The company added Charles Morris as chief medical officer and expects PRT13722 first-in-human dosing in the fourth quarter of 2026. An IND delay, a weak early trial or another Equity raise could cut the stock, and the price sits below its April offering level. By market value it ranks 4 of 4 in this group. What to watch next: the PRT13722 IND, the partnership detail and financing.

Savara (NASDAQ:SVRA): FDA Date November 22

Savara (NASDAQ:SVRA) rose 5.37% pre-market to a listed USD 4.84 on 1,147 shares, with a market capitalization of USD 994 million and an RSI of 41.2 labeled Down. Savara's lead drug MOLBREEVI, an inhaled form of GM-CSF, treats autoimmune pulmonary alveolar proteinosis, a rare lung disease, and its BLA decision is now due on November 22, 2026 after a three-month extension announced in April. The company announced presentations at the CHEST 2026 meeting in Phoenix from October 18 to 21, including a new analysis of the Phase 3 IMPALA-2 trial and long-term data on molgramostim. Second-quarter net loss was USD 40.2 million, or USD 0.16 a share, versus USD 30.4 million a year earlier, and trailing operating cash outflow is about USD 101 million. Cash and short-term investments were USD 173.0 million against USD 30.1 million of debt, and up to about USD 150 million of non-dilutive capital becomes available upon FDA approval. At the USD 994 million market value the stock is valued at about 5.7 times its cash, simple arithmetic, so much of the approval is already priced in. A complete response letter, a delay or a weaker launch would hit a stock priced for approval, and cash burn is about USD 10 million a month. By market value it ranks 1 of 4 in this group. What to watch next: the November 22 FDA decision, CHEST data and the launch plan.

Obsidian Therapeutics (NASDAQ:OBX): 67% Response, USD 350 Million Raised

Obsidian Therapeutics (NASDAQ:OBX) rose 5.16% pre-market to a listed USD 12.79 on 100 shares, with a market capitalization of USD 790 million and an RSI of 33.8 labeled Down. Obsidian Therapeutics began trading on Nasdaq as OBX on August 4, 2026 after completing its Merger with Galera Therapeutics alongside a USD 350 million private placement. Its lead program OBX-115, also called amsoki-cel, is a tumor-infiltrating lymphocyte therapy engineered with regulatable membrane-bound IL-15 that removes the need for toxic interleukin-2 dosing. OBX-115 holds FDA Fast Track and Regenerative Medicine Advanced Therapy designations, and a Phase 1 lung cancer trial has shown multiple confirmed partial responses. Cash of about USD 350 million after the deal compares with a USD 790 million market value, and the 52-week range runs from USD 4.30 to USD 49.97. Piper Sandler initiated coverage with an Overweight rating and a USD 42 target, and the average analyst target is about USD 39. Cell therapy manufacturing, small sample sizes and a recent merger listing add execution risk, and a 100-share print says nothing about demand. By market value it ranks 2 of 4 in this group. What to watch next: lung cancer Phase 1 data in 1H 2027 and the melanoma registration cohort.

Olema Pharmaceuticals (NASDAQ:OLMA): Phase 3 Pushed to 2027

Olema Pharmaceuticals (NASDAQ:OLMA) rose 4.76% pre-market to a listed USD 7.36 on 182 shares, with a market capitalization of USD 644 million and an RSI of 20.7 labeled Down, oversold. Olema reported on August 10 that enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in second- and third-line ER-positive, HER2-negative metastatic breast cancer was complete. The top-line readout, previously expected in fall 2026, is now expected in the first quarter of 2027, which pushes the key catalyst out by several months. Cash, cash equivalents and marketable securities were USD 461.1 million at June 30, down from USD 505.3 million at March 31, a drop of USD 44.2 million in one quarter. The net loss widened to USD 63.2 million from USD 43.8 million as late-stage trial spending rose, and the market value of USD 644 million is about 1.4 times cash. An earlier analyst note put the market value near USD 1.7 billion, so the equity has lost roughly 60% of that value, simple arithmetic. A binary Phase 3 outcome in 2027 and rising spending keep the stock volatile, and an oversold RSI does not predict a rebound. By market value it ranks 3 of 4 in this group. What to watch next: the OPERA-01 top-line data and quarterly cash burn.

Where Things Stand

Biotech bounces came on very thin Volume after weak trends, backed by a 67% melanoma response rate, an FDA date and a Phase 3 readout still ahead. Prelude Therapeutics (NASDAQ:PRLD) rose 6.15% with a market value of USD 298 million. Savara (NASDAQ:SVRA) rose 5.37% with a market value of USD 994 million. Obsidian Therapeutics (NASDAQ:OBX) rose 5.16% with a market value of USD 790 million. Olema Pharmaceuticals (NASDAQ:OLMA) rose 4.76% with a market value of USD 644 million. Pre-market moves on thin volume often reverse, so the balance of evidence favors waiting for the open and for filings. Direction remains unknown, and each name carries its own risks. Verify the latest filings before acting, and treat the figures as a snapshot.